PCI Biotech: Rights issue approved by the extraordinary general meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Lysaker, 6 January 2015 - An extraordinary general meeting (the "EGM") of the
shareholders of PCI Biotech Holding ASA ("PCI Biotech") was held today, 6
January 2015 at 10.00 CET. 5,508,208 shares were represented at the meeting,
corresponding to approximately 71.3 percent of the share capital.

The EGM approved the Board of Directors' proposed resolution for the rights
issue (the "Rights Issue") as set forth in the notice of the EGM issued on 9
December 2014.

Shareholders recorded in PCI Biotech's shareholders register with the Norwegian
Central Securities Depository (VPS) as at the expiry of 8 January 2015 will
receive subscription rights in the Rights Issue. Consequently, the PCI Biotech
share will, for trades subject to the ordinary T+2 settlement in VPS, trade
exclusive of the right to receive subscription rights in the Rights Issue from
and including tomorrow, 7 January 2015. Detailed terms of the Rights Issue will
be included in the prospectus, expected to be published on or about 20 January
2015.

The minutes of the EGM are attached, and are also available on
www.pcibiotech.no.

Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757

IMPORTANT NOTICE
The contents of this announcement have been prepared by, and are the sole
responsibility of, PCI Biotech. PCI Biotech's financial advisors are  acting
exclusively for PCI Biotech and  no  one  else, and will not be responsible to
anyone other  than  PCI Biotech for providing the protections afforded  to their
respective clients, or for advice in relation to the Rights Issue,  the
contents  of this announcement or any of the matters referred to herein. The
Rights Issue and the distribution of this announcement and other information in
connection with the Rights Issue may be  restricted by law in certain
jurisdictions. PCI Biotech assumes no responsibility in the event there is a
violation by any person of such restrictions. Persons into whose possession this
announcement or such other information should come are required to inform
themselves about, and to observe, any such restrictions. This announcement may
not be used for, or in connection with, and does not constitute, any offer of
securities for sale in the United States or in any other jurisdiction.

The Rights Issue will not be made in any jurisdiction or in any circumstances in
which such offer or solicitation would be unlawful. This announcement is not for
distribution, directly or indirectly in or into any jurisdiction in which it is
unlawful to make any such offer or solicitation to such person or where prior
registration or approval is required for that purpose. No steps have been taken
or will be taken relating to the Rights Issue in any jurisdiction outside of
Norway in which such steps would be required. Neither the publication and/or
delivery of this announcement shall under any circumstances imply that there has
been no change in the affairs of PCI Biotech or that the information contained
herein is correct as of any date subsequent to the earlier of the date hereof
and any earlier specified date with respect to such information.

This announcement is not for publication or distribution, directly or
indirectly, in the United States (including its territories and possessions, any
state of the United States and the District of Columbia). This announcement does
not constitute or form part of any offer or solicitation to purchase or
subscribe  for securities in the United States. Securities may not be offered or
sold in the United States absent registration or an exemption from registration.
The shares to be sold in the Rights Issue  have not been and will not be
registered under the United States Securities  Act of 1933, as amended (the "US
Securities Act") or with any securities regulatory authority of any state or
other jurisdiction of the United States, and may not be offered or sold in the
United States or to, or  for the  account of, U.S. persons (as such term is
defined in Regulation S under the US Securities Act), except pursuant to an
effective  registration statement under, or an exemption from the registration
requirements of, the US Securities Act. All offers and sales outside the United
States will be made in reliance on Regulation S under the US Securities Act.
There will be no public offer of securities in the United States. This
announcement does not constitute an offering circular or prospectus in
connection with an offering of securities of PCI Biotech. Investors must neither
accept any offer for, nor acquire, any securities to which this document refers,
unless they do so on the basis of the  information contained in the prospectus
made available by PCI Biotech only to qualified persons in certain jurisdictions
where an offer may be made (if  an offer is  made). This announcement does not
constitute an offer to sell or the solicitation of an offer to buy or subscribe
for, any securities and cannot  be relied on for any investment contract or
decision.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1884558]